News & analysis on the clinical development and manufacture of large molecule drugs
GEA releases 'comprehensive portfolio' of plug and produce pharma separator systems
By Jane Byrne
- Last updated on
GEA said its new 'aseptic' separator line enables gentle processing of human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products, while the 'pure' line is used in applications with varying hygienic requirements such as nutritional supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery.
The equipment was developed, built and tested at the GEA Westfalia Separator plant in Oelde, Germany.
“The aseptic line stands for the highest hygienic pharmaceutical requirements. The pure line provides maximum variability and is perfectly tailored to the diverse process requirements of the biopharmaceutical industry. All functions for pharmaceutical cleanliness requirements such as an automatic CIP, SIP, simple validation and a high-end qualification package are included. In addition, with the help of the cGMP validation process, the pharma separators support GEA customers in their quality standard reviews.”